Key facts
- It has raised $19.8M.
- Notable investors include CDIB Capital Group, National Development Fund of Taiwan, KGI VC.
- Status: Privately Held (backing).
- ·The complete investor list — 3 names
- ·Watchlist + deal alerts for AnBogen Therapeutics
- ·The full record, as it builds
Funding rounds
No funding rounds for AnBogen Therapeutics are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About AnBogen Therapeutics
Developer of precision cancer therapeutics developed to address unmet medical needs and improve the lives of cancer patients globally. The company is devoted to bridging the gap between research and clinical development by developing multiple oncology inhibitors for treating lung cancer, enabling the development of a differentiated pipeline in the field of precision oncology.
- Sector
- Healthcare
- HQ
- Taipei, Taiwan
- Founded
- 2019
- Website
- anbogen.com/
- Ownership
- Privately Held (backing)
AnBogen Therapeutics doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in AnBogen Therapeutics shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on AnBogen Therapeutics in its N-PORT filings yet. We sweep new filings monthly.